SCTX Short Volume
Scribe Therapeutics Inc. (SCTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $513.0M, listed on NASDAQ, employing roughly 89 people, carrying a beta of 0.00 to the broader market. Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. Led by Benjamin L. Oakes, public since 2026-07-24.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-08-28
- Short Volume
- 63.4K
- Total Volume
- 108.1K
- Short %
- 58.64%
- 30-Day Avg Short %
- 55.25%
Showing 26 days of FINRA short volume data for Scribe Therapeutics Inc..
Learn how short volume is reported and how to read the data →
Frequently asked SCTX short volume questions
- What is the daily SCTX short volume?
- As of Aug 28, 2026, Scribe Therapeutics Inc. (SCTX) short volume is 63.4K shares against 108.1K total reported volume, or 58.64% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is SCTX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does SCTX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.